AstraZeneca PLC (AZN)vsPOMDOCTOR LIMITED American Depositary Shares (POM)
AZN
AstraZeneca PLC
$157.24
-0.50%
HEALTHCARE · Cap: $243.86B
POM
POMDOCTOR LIMITED American Depositary Shares
$0.97
-5.15%
HEALTHCARE · Cap: $8.13M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 15245% more annual revenue ($61.37B vs $399.92M). AZN leads profitability with a 17.0% profit margin vs -53.2%. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
POM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$157.24
$39.44 discount
Intrinsic value data unavailable for POM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
17.2% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : POM
The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : POM
The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while POM is a growth play — different risk/reward profiles.
POM is growing revenue faster at 17.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (65/100 vs 28/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
POMDOCTOR LIMITED American Depositary Shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?